CDK4 and cancer: Through a series of in vitro and in vivo studies, we aimed to explore whether LA-CB1 could serve as a potent CDK4/6 degrader with enhanced anti-cancer effects, laying the groundwork for its further development in cancers driven by CDK4/6 signaling, particularly in challenging subtypes like TNBC.